Northern Trust’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-521,541
| Closed | -$31.2M | – | 4329 |
|
|
2019
Q4 | $31.2M | Sell |
521,541
-34,703
| -6% | -$1.3M | 0.01% | 1378 |
|
|
2019
Q3 | $15.6M | Buy |
556,244
+101,295
| +22% | +$3.46M | ﹤0.01% | 1857 |
|
|
2019
Q2 | $17.2M | Buy |
454,949
+13,685
| +3% | +$526K | ﹤0.01% | 1789 |
|
|
2019
Q1 | $17.2M | Buy |
441,264
+4,668
| +1% | +$134K | ﹤0.01% | 1808 |
|
|
2018
Q4 | $9.31M | Buy |
436,596
+52,183
| +14% | +$1.35M | ﹤0.01% | 2133 |
|
|
2018
Q3 | $15.2M | Buy |
384,413
+15,842
| +4% | +$591K | ﹤0.01% | 1993 |
|
|
2018
Q2 | $14.1M | Buy |
368,571
+119,602
| +48% | +$4.43M | ﹤0.01% | 2037 |
|
|
2018
Q1 | $7.48M | Buy |
248,969
+44,102
| +22% | +$1.49M | ﹤0.01% | 2360 |
|
|
2017
Q4 | $6.4M | Buy |
204,867
+22,799
| +13% | +$626K | ﹤0.01% | 2455 |
|
|
2017
Q3 | $5.1M | Sell |
182,068
-2,105
| -1% | -$45.7K | ﹤0.01% | 2620 |
|
|
2017
Q2 | $3.52M | Buy |
184,173
+129,681
| +238% | +$2.07M | ﹤0.01% | 2832 |
|
|
2017
Q1 | $929K | Buy |
54,492
+6,255
| +13% | +$101K | ﹤0.01% | 3367 |
|
|
2016
Q4 | $881K | Buy |
+48,237
| New | +$833K | ﹤0.01% | 3390 |
|
Northern Trust's BOLD Position: Q1 2020 in Review
Northern Trust sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 521,541 shares — an estimated $31.2M sold.
Northern Trust first reported a position in BOLD in Q4 2016 and held it in 13 quarters. The position peaked at $31.2M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- Northern Trust reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- Northern Trust sold 521,541 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $31.2M.
- Northern Trust first reported a position in Audentes Therapeutics, Inc in Q4 2016 and held it in 13 quarters.
- Northern Trust's Audentes Therapeutics, Inc position peaked at $31.2M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on Northern Trust's 13F filing for Q1 2020, filed 14 May 2020.